2018
In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers
Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Molecular Cancer Therapeutics 2018, 17: molcanther.0930.2017. PMID: 29440294, PMCID: PMC5932245, DOI: 10.1158/1535-7163.mct-17-0930.Peer-Reviewed Original ResearchConceptsEndometrial cancerXenograft modelCell linesTumor cell linesPatient-derived xenograft modelsUterine cancer cell linesAggressive endometrial cancersEndometrial cancer deathsExpression of FRαPrimary USC cell linesRecurrent endometrial cancerReceptor alpha expressionUSC cell linesImpressive antitumor activityMol Cancer TherUSC patientsCancer cell linesMedian survivalCancer deathPDX modelsPreclinical dataUterine cancerComplete resolutionIMGN853Grade 3
2014
Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract
Ahmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, Xu ML, Schwartz PE, Ratner E. Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract. International Journal Of Gynecological Cancer 2014, 24: 1250-1255. PMID: 25010039, PMCID: PMC8139417, DOI: 10.1097/igc.0000000000000201.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDiagnosis, DifferentialDoxorubicinFemaleGenital Neoplasms, FemaleGynecologic Surgical ProceduresHumansLymphoma, Non-HodgkinMiddle AgedPrednisolonePrednisonePregnancyPregnancy Complications, NeoplasticRetrospective StudiesSurvival AnalysisTeniposideVincristineYoung AdultConceptsNon-Hodgkin lymphomaFemale genital tractGenital tractGynecologic malignanciesPara-aortic lymph nodesPrimary non-Hodgkin lymphomaDiffuse large B-cell lymphomaYale-New Haven HospitalLarge B-cell lymphomaConcomitant radiation therapyRadical gynecologic surgeryCommon histologic typeOverall median survivalSingle institution experienceStem cell transplantationRare gynecologic malignancyDiagnosis of lymphomaAnn Arbor systemB-cell lymphomaWorld Health OrganizationMedian survivalRecurrent diseaseCombination chemotherapyMedian ageUterine corpus
2009
Brain Metastases in Epithelial Ovarian and Primary Peritoneal Carcinoma
Ratner ES, Toy E, O'Malley DM, Mcalpine J, Rutherford TJ, Azodi M, Higgins SA, Schwartz PE. Brain Metastases in Epithelial Ovarian and Primary Peritoneal Carcinoma. International Journal Of Gynecological Cancer 2009, 19: 856-859. PMID: 19574773, DOI: 10.1111/igc.0b013e3181a83301.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyPrimary peritoneal cancerBrain metastatic diseaseEpithelial ovarian cancerGamma knife radiosurgeryBrain metastasesKnife radiosurgeryRadiation therapySingle lesionPostoperative whole-brain radiation therapyCentral nervous system metastasesLargest single-institution experienceNervous system metastasesPrimary peritoneal carcinomaShorter median timeSingle institution experienceMultiple brain lesionsLong-term survivalEpithelial ovarianMedian survivalPaclitaxel therapyPeritoneal cancerPeritoneal carcinomaMetastatic diseaseRetrospective review
2007
Carcinosarcoma of the ovary
SILASI D, ILLUZZI JL, KELLY MG, RUTHERFORD TJ, MOR G, AZODI M, SCHWARTZ PE. Carcinosarcoma of the ovary. International Journal Of Gynecological Cancer 2007, 18: 22-29. PMID: 17451459, DOI: 10.1111/j.1525-1438.2007.00948.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinosarcomaChemotherapy, AdjuvantCisplatinCombined Modality TherapyDisease-Free SurvivalFemaleHumansIfosfamideMiddle AgedOvarian NeoplasmsPaclitaxelRegistriesRetrospective StudiesSurvival RateTreatment OutcomeConceptsProgression-free intervalMedian progression-free intervalAdvanced stage diseaseMedian survivalOptimal cytoreductionOvarian carcinosarcomaStage diseaseTaxol groupEffective cytotoxic regimenFirst-line cisplatinFirst-line chemotherapyCombination of carboplatinEpithelial ovarian cancerCytotoxic regimenIfosfamide groupAdjuvant cisplatinEntire cohortMedical recordsOvarian cancerCytoreductionPatientsSurvival rateCarcinosarcomaCarboplatinCisplatin